IMV Inc. Stock Toronto S.E.
Equities
IMV
CA44974L3011
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 30.6M 42.16M |
---|---|---|---|---|---|
Net income 2021 | -36M -49.59M | Net income 2022 | -38M -52.35M | EV / Sales 2021 | - |
Net cash position 2021 | 18.96M 26.12M | Net Debt 2022 | 7.67M 10.57M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.47
x | P/E ratio 2022 |
-0.53
x | Employees | 63 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.93% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 20-11-09 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 58 | 20-06-30 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 21-03-31 |
Markus Warmuth
BRD | Director/Board Member | 53 | 18-11-05 |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.65% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |